{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:48:20Z","timestamp":1744811300332},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.01). Discontinuation of the therapy after the first injection was neither dependent on the presence of incontinence at baseline (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.73) nor it was related to age (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.6). On univariate analyses, none of the parameters evaluated was useful of predicting successful response, although there was a trend in women who had had a previous midurethral sling surgery for stress urinary incontinence, to have a lower chance of having a positive response after the first injection (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.06).<\/jats:p>\n            <jats:p>Thirty-nine women (29%) had at least 1 adverse event, urinary tract infection, and straining to void were the most frequent. Women above 65\u200ayears old had less risk of developing a urinary tract infection (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.04).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/j.pbj.0000000000000164","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T04:19:51Z","timestamp":1652933991000},"page":"e164","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients\u2019 expectations"],"prefix":"10.1097","volume":"7","author":[{"given":"Pedro","family":"Abreu-Mendes","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Urologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o"},{"name":"Faculdade de Medicina, Universidade do Porto, Porto, Portugal."}]},{"given":"In\u00eas","family":"Portugal-Rodrigues","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Universidade do Porto, Porto, Portugal."}]},{"given":"Luis","family":"Vale","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Urologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o"},{"name":"Faculdade de Medicina, Universidade do Porto, Porto, Portugal."}]},{"given":"Paulo","family":"Dinis","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Urologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o"},{"name":"Faculdade de Medicina, Universidade do Porto, Porto, Portugal."}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Urologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o"},{"name":"Faculdade de Medicina, Universidade do Porto, Porto, Portugal."}]},{"given":"Tiago","family":"Antunes-Lopes","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Urologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o"},{"name":"Faculdade de Medicina, Universidade do Porto, Porto, Portugal."}]},{"given":"Carlos","family":"Martins-Silva","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Urologia, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o"},{"name":"Faculdade de Medicina, Universidade do Porto, Porto, Portugal."}]}],"member":"276","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"R1-20241001","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int."},{"issue":"27","key":"R2-20241001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2019.02.005","article-title":"The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis","volume":"1","author":"Lozano-Ortega","year":"2019","journal-title":"Urology."},{"key":"R3-20241001","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5301\/uro.5000120","article-title":"OnabotulinumtoxinA intravesical treatment in patients affected by overactive bladder syndrome: best practice in real- life management","volume":"82","author":"Giannantoni","year":"2015","journal-title":"Urologia."},{"key":"R4-20241001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology."},{"key":"R5-20241001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn."},{"key":"R6-20241001","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol."},{"key":"R7-20241001","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.euf.2018.05.004","article-title":"Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment?","volume":"4","author":"Marcelissen","year":"2018","journal-title":"Eur Urol Focus."},{"key":"R8-20241001","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur Urol."},{"key":"R9-20241001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol."},{"key":"R10-20241001","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol."},{"issue":"(2S)","key":"R11-20241001","first-page":"S216","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"197","author":"Nitti","year":"2017","journal-title":"J Urol."},{"issue":"(pt A)","key":"R12-20241001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2015.07.333","article-title":"Use of botulinum toxin for genitourinary conditions: what is the evidence?","volume":"107","author":"Da Silva","year":"2015","journal-title":"Toxicon."},{"key":"R13-20241001","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/21681805.2017.1334697","article-title":"Clinical practice of BOTOX((R)) treatment for overactive bladder syndrome in Sweden: an assessment of resource use and external validity","volume":"51","author":"Gralen","year":"2017","journal-title":"Scand J Urol."},{"issue":"(6S)","key":"R14-20241001","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol."},{"key":"R15-20241001","doi-asserted-by":"crossref","first-page":"e0147137","DOI":"10.1371\/journal.pone.0147137","article-title":"Factors associated with therapeutic efficacy of intravesical onabotulinumtoxina injection for overactive bladder syndrome","volume":"11","author":"Hsiao","year":"2016","journal-title":"PLoS One."},{"key":"R16-20241001","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOU.0b013e32832ae176","article-title":"Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?","volume":"19","author":"Da Silva","year":"2009","journal-title":"Curr Opin Urol."},{"key":"R17-20241001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00345-016-1862-y","article-title":"Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms","volume":"35","author":"Marcelissen","year":"2017","journal-title":"World J Urol."},{"key":"R18-20241001","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/iju.12188","article-title":"Botulinum toxin treatment for bladder dysfunction","volume":"20","author":"Santos-Silva","year":"2013","journal-title":"Int J Urol."},{"key":"R19-20241001","doi-asserted-by":"crossref","first-page":"555","DOI":"10.17219\/acem\/90764","article-title":"How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA","volume":"28","author":"Przydacz","year":"2019","journal-title":"Adv Clin Exp Med."},{"key":"R20-20241001","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.juro.2017.04.103","article-title":"Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence","volume":"198","author":"Richter","year":"2017","journal-title":"J Urol."},{"key":"R21-20241001","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J Urol."},{"key":"R22-20241001","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00192-015-2839-x","article-title":"Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery","volume":"27","author":"Miotla","year":"2016","journal-title":"Int Urogynecol J."},{"key":"R23-20241001","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur Urol."},{"key":"R24-20241001","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int."},{"key":"R25-20241001","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00192-016-3212-4","article-title":"Urinary retention in female OAB after intravesical Botox injection: who is really at risk?","volume":"28","author":"Miotla","year":"2017","journal-title":"Int Urogynecol J."}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:04:19Z","timestamp":1727809459000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/j.pbj.0000000000000164","relation":{},"ISSN":["2444-8664"],"issn-type":[{"type":"electronic","value":"2444-8664"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"2020-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}